Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
October 09, 2024 08:45 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Sonnet to receive $1.0 million in upfront payment and up to an additional$1.0 million in milestone payments with a royalty in the low double digits on net sales, less certain expenses, in the India...
Peripheral Neuropathy Market Size to Surpass US$ 2.38 Billion By 2032, Driven by Rising Diabetes and Nerve Damage Cases | Research by SNS Insider
July 11, 2024 12:52 ET
|
SNS Insider pvt ltd
Pune, July 11, 2024 (GLOBE NEWSWIRE) -- Peripheral Neuropathy Market Analysis: “The Peripheral Neuropathy Market size was valued at US$ 1.48 billion in 2023, estimated to reach US$ 2.38 billion...
U.S. Neuropathic Pain Treatment Market to surpass US$ 2,994.0 Million by 2030, Says Coherent Market Insights (CMI)
March 06, 2023 09:20 ET
|
CMI
Burlingame, March 06, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights’ analysis, the U.S. neuropathic pain treatment market is estimated to be valued at US$ 2,064.9 Million in 2022...
Global Peripheral Neuropathy Treatment Market to Surpass US$ 2,425.9 Million by 2030, Says Coherent Market Insights (CMI)
June 21, 2022 08:40 ET
|
CMI
Seattle, June 21, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global peripheral neuropathy treatment market is estimated to be valued at US$ 1,795.10 million in 2022 and is...
Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles
January 14, 2021 18:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles Diabetic...
Aptinyx to Present at Upcoming Virtual Investor Conferences
June 16, 2020 08:37 ET
|
Aptinyx Inc.
EVANSTON, Ill., June 16, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
May 14, 2020 16:03 ET
|
Aptinyx Inc.
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations...
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
April 30, 2020 08:47 ET
|
Aptinyx Inc.
EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 30, 2020 16:01 ET
|
Aptinyx Inc.
Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common...
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
March 18, 2020 16:01 ET
|
Aptinyx Inc.
EVANSTON, Ill., March 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...